Calvisi Diego F, Ladu Sara, Pinna Federico, Frau Maddalena, Tomasi Maria L, Sini Marcella, Simile Maria M, Bonelli Piero, Muroni Maria R, Seddaiu Maria A, Lim Dae-Sik, Feo Francesco, Pascale Rosa M
Department of Biomedical Sciences, Division of Experimental Pathology and Oncology, University of Sassari, Sassari, Italy.
Gastroenterology. 2009 Nov;137(5):1816-26.e1-10. doi: 10.1053/j.gastro.2009.08.005. Epub 2009 Aug 15.
BACKGROUND & AIMS: The cell cycle regulators P21(WAF1), P27(KIP1), P57(KIP2), P130, RASSF1A, and FOXO1 are down-regulated during hepatocellular carcinoma (HCC) pathogenesis. We investigated the role of the ubiquitin ligase subunits CKS1 and SKP2, which regulate proteasome degradation of cell cycle regulators, in HCC progression.
Human HCC tissues from patients with better (HCCB, >3 years survival) and poorer prognosis (HCCP, <3 years survival) and HCC cell lines were analyzed.
The promoters of P21(WAF1), P27(KIP1), and P57(KIP2) were more frequently hypermethylated in HCCP than HCCB. Messenger RNA levels of these genes were up-regulated in samples in which these genes were not methylated; protein levels increased only in HCCB because of CKS1- and SKP2-dependent ubiquitination of these proteins in HCCP. The level of SKP2 expression correlated with rate of HCC cell proliferation and level of microvascularization of samples and was inversely correlated with apoptosis and survival. In HCCB, SKP2 activity was balanced by degradation by the ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C)-CDH1 and up-regulation of SKP2 suppressor histidine triad nucleotide binding protein 1 (HINT1). In HCCP, however, SKP2 was not degraded because of down-regulation of the phosphatase CDC14B, CDK2-dependent serine phosphorylation (which inhibits interaction between CDH1 and SKP2), and HINT1 inactivation. In HCC cells, small interfering RNA knockdown of SKP2 reduced proliferation and ubiquitination of the cell cycle regulators, whereas SKP2 increased proliferation and reduced expression of cell cycle regulators.
Ubiquitination and proteasome degradation of P21WAF1, P27KIP1, P57KIP2, P130, RASSF1A, and FOXO1 and mechanisms that prevent degradation of SKP2 by APC/C-CDH1 contribute to HCC progression. CKS1-SKP2 ligase might be developed as a therapeutic target or diagnostic marker.
细胞周期调节因子P21(WAF1)、P27(KIP1)、P57(KIP2)、P130、RASSF1A和FOXO1在肝细胞癌(HCC)发病过程中表达下调。我们研究了泛素连接酶亚基CKS1和SKP2在HCC进展中的作用,它们可调节细胞周期调节因子的蛋白酶体降解。
分析了预后较好(HCCB,生存>3年)和较差(HCCP,生存<3年)的患者的人HCC组织以及HCC细胞系。
与HCCB相比,P21(WAF1)、P27(KIP1)和P57(KIP2)的启动子在HCCP中更频繁地发生高甲基化。这些基因的信使RNA水平在未甲基化的样本中上调;由于HCCP中这些蛋白的CKS1和SKP2依赖性泛素化,蛋白水平仅在HCCB中增加。SKP2的表达水平与HCC细胞增殖率和样本微血管化水平相关,与细胞凋亡和生存率呈负相关。在HCCB中,SKP2的活性通过泛素连接酶后期促进复合物/细胞周期体(APC/C)-CDH1的降解以及SKP2抑制因子组氨酸三联体核苷酸结合蛋白1(HINT1)的上调而得到平衡。然而,在HCCP中,由于磷酸酶CDC14B的下调、CDK2依赖性丝氨酸磷酸化(抑制CDH1与SKP2之间的相互作用)以及HINT1失活,SKP2未被降解。在HCC细胞中,小干扰RNA敲低SKP2可降低细胞周期调节因子的增殖和泛素化,而SKP2则增加增殖并降低细胞周期调节因子的表达。
P21WAF1、P27KIP1、P57KIP2、P130、RASSF1A和FOXO1的泛素化和蛋白酶体降解以及阻止APC/C-CDH1降解SKP2的机制促进了HCC的进展。CKS1-SKP2连接酶可能被开发为治疗靶点或诊断标志物。